[News] CAR T-cell therapy in refractory large B-cell lymphoma

Recently published results have shown that axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is active and safe in patients with refractory large B-cell lymphoma.

Source: The Lancet Oncology - December 14, 2017 Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research